Revisión

Neurotransmitters in Alzheimer’s disease

S. Manzano-Palomo, M.A. De la Morena-Vicente, M.S. Barquero [REV NEUROL 2006;42:350-353] PMID: 16575771 DOI: https://doi.org/10.33588/rn.4206.2005219

OPEN ACCESS

Volumen 42 | Number 06 | Nº of views of the article 35.368 | Nº of PDF downloads 3.019 | Article publication date 16/03/2006

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

AIM To review the current state of the art in neurotransmission in Alzheimer’s disease (AD) and its involvement in the pathophysiology of the disease.

INTRODUCTION AD is a neurodegenerative disorder that is estimated to affect 15 million people around the world. Since the cholinergic hypothesis of AD was put forward 20 years ago, numerous studies have been conducted in an attempt to determine the role that neurotransmitters play in AD. Among other things, this has made it possible to develop drugs based on the inhibition of acetylcholinesterase. DEVELOPMENT. The monoaminergic neurotransmission systems are examined, with special attention given to the cholinergic system, and their anatomical distribution, function, receptors, activity and degradation systems are also described. Peptidergic neurotransmission systems are only briefly discussed, since they are not the main objective of this report. We also review the cholinergic hypothesis and the possible interrelations between cholinergic neurotransmission and b-amyloid metabolism, as well as the potential involvement of acetylcholinesterase inhibitor drugs in more fundamental pathophysiological mechanisms, which act with a neuroprotective component. KeywordsAcetylcholine Alzheimer’s disease Muscarinic receptors Neurotransmitters Nicotinic receptors CategoriesDemencia Neurodegeneración

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Revisión

Neurotransmitters in Alzheimer’s disease